- Home
- CSCI vs PHIO Comparison
CSCI vs PHIO Comparison
Compare CSCI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- PHIO
- Stock Information
- Founded
- CSCI 1990
- PHIO 2011
- Country
- CSCI Canada
- PHIO United States
- Employees
- CSCI N/A
- PHIO N/A
- Industry
- CSCI
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- PHIO Health Care
- Exchange
- CSCI NYSE
- PHIO Nasdaq
- Market Cap
- CSCI 10.5M
- PHIO 8.6M
- IPO Year
- CSCI 1996
- PHIO N/A
- Fundamental
- Price
- CSCI $3.37
- PHIO $2.16
- Analyst Decision
- CSCI
- PHIO Strong Buy
- Analyst Count
- CSCI 0
- PHIO 2
- Target Price
- CSCI N/A
- PHIO $9.00
- AVG Volume (30 Days)
- CSCI 2.1K
- PHIO 703.0K
- Earning Date
- CSCI 08-12-2025
- PHIO 08-13-2025
- Dividend Yield
- CSCI N/A
- PHIO N/A
- EPS Growth
- CSCI N/A
- PHIO N/A
- EPS
- CSCI N/A
- PHIO N/A
- Revenue
- CSCI $9,030,000.00
- PHIO N/A
- Revenue This Year
- CSCI N/A
- PHIO N/A
- Revenue Next Year
- CSCI N/A
- PHIO N/A
- P/E Ratio
- CSCI N/A
- PHIO N/A
- Revenue Growth
- CSCI 36.51
- PHIO N/A
- 52 Week Low
- CSCI $1.96
- PHIO $0.97
- 52 Week High
- CSCI $7.54
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- PHIO 50.19
- Support Level
- CSCI N/A
- PHIO $2.11
- Resistance Level
- CSCI N/A
- PHIO $2.30
- Average True Range (ATR)
- CSCI 0.00
- PHIO 0.21
- MACD
- CSCI 0.00
- PHIO -0.04
- Stochastic Oscillator
- CSCI 0.00
- PHIO 9.65
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.